EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

20/20 Biolabs, Inc. (AIDX) fair value: what the stock is really worth

We calculate from audited financials what 20/20 Biolabs, Inc. is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Valuation from Jun 23, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US90138K1016

22 20/20 Biolabs, Inc. logo Thin data Jun 23, 2026

20/20 Biolabs, Inc.

AIDX · US

Low PriorityFair Value upside is limited and quality is weak.

·Fair value $0.4080 · Fairly valued (−4%)
!Quality 44/100
!Weak Growth (revenue 5y −2.6 %/yr)
!Loss-making · -182.8% net margin (FY2025)
!Negative equity (buybacks among others) · negative free cash flow
!Trails peers (1/6)
!Narrow moat 9/100
!Evidence only low, so the estimate is less certain
!Weak on valuation: 27 out of 100
Watch 20/20 Biolabs, Inc. Common Stock for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$23.85 $0.4000 Fair Value $0.4080 Feb 2026 Sep 2026

White line = price, green steps = our fair value per fiscal year. As of Jun 23, 2026.

How to read this chart

7‑month range $0.4000 – $23.85 · fair‑value band $0.3060 – $0.5100 · the $0.4266 price screens above the $0.4080 fair value. As of Jun 23, 2026.

Follow 20/20 Biolabs, Inc. Common Stock in your weekly email

Every Wednesday you see whether 20/20 Biolabs, Inc. Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers.

Show more

20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.

Stock analysis

20/20 Biolabs, Inc. Common Stock (AIDX) currently trades at $0.4266, while our model-based Fair Value estimate is $0.4080, implying the stock looks roughly 4.6% fairly valued today.

Show more

Valuation

How firm this estimate is: it rests on 3 models at a data quality of 80/100, which puts the evidence level at low.

Scenario range: $0.3060 (bear) to $0.5100 (bull), the price of $0.4266 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

20/20 Biolabs, Inc. Common Stock reported revenue of $2.0M in FY2025 versus $9.6M in FY2021, a compound −32.1%/yr. Reported net income was −$3.7M in FY2025.

Key figures

Market cap $6.1M · P/S ratio 3.30 · EPS (TTM) $−0.4900 · Net margin −279% · Return on equity −242% · Return on assets (EBIT) −44.8% · Operating margin −408% · Revenue (TTM) $1.8M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −4%, AIDX screens richer than that median.

Notify me when AIDX reaches fair value

Put AIDX on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 44/100

Of which business quality 45 · Market factors (momentum, volatility) 19

Profitability 5
Margins and returns on capital today
Quality Growth 75
Are margins and returns improving?
Cashflow 50
Earnings quality: real cash, not paper profit
Fin. Strength 46
Balance sheet, leverage, solvency risk
Investment 67
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 9
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 50
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+16.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−43.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.6%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−87.1% (2020) → −162.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch AIDX, get fair value alerts →

Compare 20/20 Biolabs, Inc. Common Stock with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 44 · Below median
Fair Value upside −4% · Above median
Profitability
Return on equity (TTM) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −59% · Bottom 25%
Net margin (TTM) −183% · Bottom 25%
Growth and dividend
Revenue growth −36% · Bottom 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM) 3.30× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)27 · sector 10
FUTURE (revenue growth)0 · sector 31
PAST (return on equity)0 · sector 7
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 40

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $103.69 $74.79 −28%
Stryker Corporation SYK $275.09 $302.60 +10%
Medtronic plc MDT $90.77 $65.57 −28%
Boston Scientific Corporation BSX $44.92 $49.41 +10%
Edwards Lifesciences Corporation EW $88.78 $82.04 −8%
Siemens Healthineers AG SHL €37.43 €35.22 −6%
DexCom, Inc DXCM $89.53 $98.48 +10%
GE HealthCare Technologies Inc GEHC $66.27 $69.62 +5%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥156.68 ¥172.35 +10%
Koninklijke Philips N.V PHIA €21.85 €15.32 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

20/20 Biolabs, Inc. Common Stock · Fair Value
$0.4080 −5%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "20/20 Biolabs, Inc. Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/AIDX

Frequently asked questions

Is 20/20 Biolabs, Inc. (AIDX) overvalued or undervalued?
As of Jun 23, 2026, our model estimates a fair value of $0.4080 versus a price of $0.4266, about −4% upside (fairly valued).
What is the fair value of AIDX?
Our model-based fair value for 20/20 Biolabs, Inc. Common Stock is $0.4080 (as of Jun 23, 2026), built from audited fundamentals. The current price: $0.4266.
What is the quality score of AIDX?
20/20 Biolabs, Inc. Common Stock has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for 20/20 Biolabs, Inc. (AIDX)?
Our model-based price target is the fair value of $0.4080 (as of Jun 23, 2026) from 3 valuation models. Cautious scenario $0.3060, optimistic scenario $0.5100. It is a calculation from audited fundamentals, not an analyst target.
What is the 20/20 Biolabs, Inc. Common Stock stock forecast for 2026?
Our models put fair value at $0.4080, about −4% upside versus a price of $0.4266 (fairly valued). Cautious scenario $0.3060, optimistic scenario $0.5100. The calculation is refreshed regularly with new filings.
What is the revenue of 20/20 Biolabs, Inc. (AIDX)?
20/20 Biolabs, Inc. Common Stock reported trailing-twelve-month revenue of about $1.8M (latest available figure, as of Jun 23, 2026).
What is the intrinsic value of 20/20 Biolabs, Inc. (AIDX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For 20/20 Biolabs, Inc. Common Stock it is $0.4080 per share (as of Jun 23, 2026), against a price of $0.4266. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is 20/20 Biolabs, Inc. Common Stock stock overvalued or undervalued in 2026?
As of Jun 23, 2026, AIDX trades above its calculated fair value: price $0.4266, fair value $0.4080, a gap of about −4% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AIDX?
No. The price is what the market pays today ($0.4266); the fair value is what the company's own numbers justify ($0.4080). For 20/20 Biolabs, Inc. Common Stock the two are $0.0186 per share apart. That gap is exactly why we show both numbers side by side.
How much is 20/20 Biolabs, Inc. Common Stock worth?
The market values 20/20 Biolabs, Inc. Common Stock at about $6.1M (market capitalisation, as of Jun 23, 2026). Per share that is $0.4266; our models calculate a fair value of $0.4080 per share.
What do the bullish and bearish scenarios say about AIDX?
Our models span a range for 20/20 Biolabs, Inc. Common Stock: cautious scenario $0.3060, base $0.4080, optimistic $0.5100 per share (as of Jun 23, 2026, price $0.4266). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of 20/20 Biolabs, Inc. (AIDX)?
Balance-sheet figures for 20/20 Biolabs, Inc. Common Stock (as of Jun 23, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
Which stocks are comparable to 20/20 Biolabs, Inc. Common Stock?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is 20/20 Biolabs, Inc. Common Stock stock attractive at the current price?
The data as of Jun 23, 2026: price $0.4266, calculated fair value $0.4080 (−4%), Quality Score 44/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AIDX calculated?
We run 20/20 Biolabs, Inc. Common Stock through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.4080, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. 20/20 Biolabs, Inc. Common Stock itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of 20/20 Biolabs, Inc. (AIDX)?
The closing price on Sep 23, 2026 was $0.4266. Our model-based fair value is $0.4080, about −4% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with 20/20 Biolabs, Inc. Common Stock right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of 20/20 Biolabs, Inc. Common Stock

How large is the market capitalisation of 20/20 Biolabs, Inc. (AIDX)?
The market capitalisation of 20/20 Biolabs, Inc. Common Stock is $6.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of 20/20 Biolabs, Inc. (AIDX)?
The price-to-sales ratio of 20/20 Biolabs, Inc. Common Stock is 3.30 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of 20/20 Biolabs, Inc. (AIDX)?
Earnings per share at 20/20 Biolabs, Inc. Common Stock are $−0.4900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of 20/20 Biolabs, Inc. (AIDX)?
The net margin of 20/20 Biolabs, Inc. Common Stock is −279% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of 20/20 Biolabs, Inc. (AIDX)?
The return on equity (ROE) of 20/20 Biolabs, Inc. Common Stock is −242% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of 20/20 Biolabs, Inc. (AIDX)?
On an EBIT basis the return on assets of 20/20 Biolabs, Inc. Common Stock is −44.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of 20/20 Biolabs, Inc. (AIDX)?
The operating margin of 20/20 Biolabs, Inc. Common Stock is −408% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at 20/20 Biolabs, Inc. (AIDX)?
Revenue at 20/20 Biolabs, Inc. Common Stock is growing −36.2% versus a year earlier (3y avg −43.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does 20/20 Biolabs, Inc. (AIDX) generate?
The free cash flow of 20/20 Biolabs, Inc. Common Stock is −$1.9B (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does 20/20 Biolabs, Inc. (AIDX) carry?
The net debt of 20/20 Biolabs, Inc. Common Stock is $258M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch 20/20 Biolabs, Inc. Common Stock in the live analysis

One click puts 20/20 Biolabs, Inc. Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.